Oral vs injectable BPC-157: which route works for what

The two routes are not competing versions of the same thing. They put the peptide in different places. A capsule delivers it to the stomach and intestinal lining, where the gut studies say it acts. A subcutaneous injection puts it in the bloodstream and, if injected nearby, the tissue around an injury. The table summarizes where each route stands.

Most peptides are destroyed in the stomach within minutes. Acid unfolds them and enzymes cut them into amino acids, which is why insulin is injected and why nearly every peptide on this site is sold as an injectable. BPC-157 is the exception. Its 15 amino acid sequence comes from a protective protein found in human gastric juice, and the original research group reported it stays intact in gastric acid for at least 24 hours. Stability in the environment it came from is the whole reason the oral route exists.

Surviving the stomach is not the same as crossing into the blood. The gut lining is a selective barrier, and a 1,400 dalton peptide does not pass it freely. Animal pharmacokinetic work has detected BPC-157 and its fragments systemically after oral dosing, but at what fraction, and whether that fraction reaches a tendon at a meaningful concentration, has not been measured in a human. The most defensible statement is that oral BPC-157 reliably reaches the gut lining and unreliably reaches anything else.

The gut literature is the deepest part of the BPC-157 record. Rats given the peptide in drinking water or by gavage showed protection of the stomach lining against NSAIDs and alcohol, faster healing of chemically induced colitis, closure of fistulas, and improved recovery from various intestinal injuries. Doses in those studies were weight based, commonly 10 mcg per kg and 10 ng per kg, and both ends of that range produced effects, which is one reason human dosing is so loosely defined.

The one area with human data also points to the gut. Small early phase trials for inflammatory bowel disease were run and described as favorable, though they were never published as full controlled trials. That is thin, but it is more than the tendon indication has. The compound page rates gut lining protection and repair as moderate on the strength of the animal work, and that rating applies to the oral route specifically.

A practical note from the protocols: oral doses for gut use are typically taken away from food, on the theory that the peptide should contact the lining directly rather than mix into a meal. There is no trial behind the timing.

The tendon studies that made BPC-157 famous, surgically cut Achilles tendons in rats healing faster with stronger tendon-to-bone reattachment, used injection. So did the muscle crush, ligament and fracture work. Some of those studies dosed systemically, by intraperitoneal injection well away from the injury, and still found benefit, which is why the compound page says injecting right at the injury is not strictly necessary. Local injection remains the community default on the theory that concentration at the site helps.

The case against oral for these uses is simply the absence of data. Nobody has shown that a swallowed dose reaches an injured tendon at a concentration comparable to a subcutaneous dose, and the plasma half-life is under 30 minutes either way, so a small absorbed fraction would be gone quickly. Injection removes the question. The injection sites page covers the practical side, and the BPC-157 vs TB-500 comparison explains why the usual pairing injects both.

Never inject directly into a tendon or joint capsule without clinical training. Subcutaneous near the injury, which means into the fat layer over it, is what the protocols describe.

Most injectable BPC-157 is sold as an acetate salt, the standard form from peptide synthesis. Arginate BPC-157 pairs the peptide with arginine as the counter ion instead, and vendors market it as a more stable form for oral use, claiming better resistance to digestion and higher bioavailability. The peptide itself is identical; only the salt differs.

The claim is plausible in a general sense, since counter ion choice can affect peptide stability, but no published human study compares arginate to acetate BPC-157 by any route. The stability data that supports oral use at all was generated with the standard form. Treat arginate as a formulation choice some vendors offer, priced higher, with a benefit that has not been demonstrated rather than one that has been disproven. Some people skip capsules entirely and drink a measured volume of reconstituted injectable solution, which works for gut use if the goal is contact with the lining.

The reported ranges are the same for both routes, which tells you how little the dosing is grounded in pharmacokinetics. Community protocols and the compound page converge on 250 to 500 mcg once or twice daily by injection, with some protocols going to 1 mg per day for acute injuries. Oral capsules are commonly sold at 500 mcg each and taken once or twice daily; injectable protocols for gut complaints use the same 250 to 500 mcg.

The compound page's protocol table reads: acute soft tissue injury, 500 mcg twice daily, subcutaneous near the injury; chronic tendon or ligament issue, 250 to 500 mcg once daily; gut complaints, 250 to 500 mcg once or twice daily by capsule or injection; general recovery, 250 mcg once daily subcutaneous. Cycles of 4 to 8 weeks are usual, or simply until the injury has healed. None of this comes from a human dose finding study, and the peptide dosage chart flags it the same way.

For injection, a 5 mg vial reconstituted with 2 mL of bacteriostatic water gives 2.5 mg per mL, so 250 mcg is 10 units on an insulin syringe and 500 mcg is 20 units. The calculator handles other combinations.

Injectable is cheaper per dose. A 10 mg vial holds 20 doses of 500 mcg, and at typical research vendor prices that works out to a fraction of a dollar per dose plus the cost of bacteriostatic water and syringes. Capsules are sold in bottles of 30 to 60 at 500 mcg each, and the per dose price is usually several times higher, with arginate forms at the top. The premium pays for the convenience of no needles and no reconstitution, which for a gut-focused protocol is a fair trade for many people.

The hidden cost is uncertainty. Capsules are harder to verify: a third party COA for a lyophilized vial tests the powder directly, while a capsule COA tests a product that has been mixed with excipients and encapsulated, and quantity per capsule is rarely reported. How to read a COA explains what to look for in either case.

Gut complaints: oral is the evidence-matched route, and the only one where human pilot data exists. Tendon, ligament, muscle or bone: injectable, subcutaneous near the injury or in the abdomen, because that is what the animal studies did and oral delivery to those tissues is unmeasured. Both at once, for someone with a gut issue and an injury, is a pattern that appears in protocols, usually alongside KPV for the gut side; the BPC-157 and KPV stack page covers that pairing.

If the injection is the obstacle, oral is a weaker bet for a tendon than no treatment is a bad one; some users report benefit, no study supports it, and the cost of trying is low. Just do not read a gut study as proof it will reach a shoulder.